James R. Berenson, MD, Inc.

Archive | Papers RSS feed for this section

Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects

March 5, 2017

Abstract

Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been implicated in polyubiquitin-mediated IL-1R/TLR signaling through activation of IκB kinase

… Article

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

March 5, 2017

0 Comments

Michael Ghermezi, Mingjie Li, Suzie Vardanyan, Nika Manik Harutyunyan, Jillian Gottlieb, Ariana Berenson, Tanya M. Spektor, Claudia Andreu-Vieyra, Sophia Petraki, … Article

Outcomes in Multiple Myeloma Patients Evaluated

March 5, 2017

0 Comments

There appears to be marked improvement in overall survival in people with multiple myeloma, according to a study involving 264

… Article

← More posts

Multiple myeloma (active) is the most common type plasma cell cancer. However, the following are other forms of myeloma or myeloma-related conditions:

Monoclonal gammopathy of undetermined significance (MGUS)
Asymptomatic (smoldering/indolent) myeloma
solitary plasmacytoma of the bone
Extramedullary plasmacytoma
Light chain myeloma
Non-secretory myeloma
Osteosclerotic myeloma (POEMS syndrome)
Waldenstrom macroglobulinemia
Light chain amyloidosis
Plasma cell leukemia

Archive | Papers RSS feed for this section

Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects

Abstract

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

Outcomes in Multiple Myeloma Patients Evaluated

James R. Berenson, MD

Links

Subscribe

Contact Us